More Minds, More Impact − New Members Join the VICT3R Community

We are proud to announce the expansion of the VICT3R consortium with the addition of new beneficiaries joining the project and organisations joining the VICT3R Associated Contract Research Organisation (CRO) Network. This growing network of organisations strengthens our mission to transform the way safety is evaluated in drug and chemical development by reducing reliance on laboratory animals.

The newly joined beneficiaries include first-line industry partners Servier Group and Zoetis Belgium SA.

• Servier is an independent international pharmaceutical group governed by a foundation, committed to therapeutic innovation.

• Zoetis is the world’s leading animal health company.

 
Additionally, the project welcomes CAATevents gGmbH, an SME (small and medium-sized enterprise) established in Germany as a non-for-profit to support CAAT-US and CAAT-Europe, focused on the development and validation of alternatives to animal testing.

These additions bring the VICT3R consortium to a total of 37 partner organisations across 12 countries, comprising six academic institutions, eight SMEs and 23 industry partners across human, veterinary, and crop science sectors. With this expansion, the total project budget has increased to approximately €30 million.

“Given its potential for reducing the number of animals used in toxicology testing, the VICT3R project is generating great interest from industry stakeholders across different sectors, as reflected in the high number of companies involved in the project.” – Ferran Sanz (Pompeu Fabra University, Spain) VICT3R Project Coordinator

In addition, other organisations have formally joined the VICT3R Community through the signing of Associated CRO Agreements: Charles River Laboratories International Inc., Scantox A/S and Labcorp. These organisations contribute valuable study data and decades of experience to support the development of Virtual Control Groups (VCGs) − a cornerstone of the VICT3R project.

• Charles River is a leading, global provider of drug discovery, development, and manufacturing solutions.

• Scantox A/S is preclinical contract research organisation supporting pharmaceutical, biotech and medical device companies in drug development.

• Labcorp is a global leader of innovative and comprehensive laboratory services.

“With the addition of the new partners, VICT3R will increase its outreach and momentum. The CROs and laboratory will contribute to the speed of uptake of VCGs in pre-clinical testing.” – Thomas Steger-Hartmann (Bayer, Germany), VICT3R Project Lead

We’re very excited to welcome the new organisations joining our growing Community! Together, we’re advancing the development and implementation of VCGs and paving the way toward a more ethical and robust future for safety science.

For the full overview of VICT3R Community members, see: